Cytek Biosciences, Inc. (CTKB) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Medical - Devices
EV/EBITDA
↑
N/A
—
5yr avg: 234.79
P/FCF
↓
N/A
—
5yr avg: 3654.12
30Y Low38.8·High38.8
P/B Ratio
↓
1.72
↓-46% vs avg
5yr avg: 3.18
30Y Low1.9·High5.4
ROE
↓
-18.0%
↑-343% vs avg
5yr avg: -4.1%
30Y Low-18%·High2%
Debt/EBITDA
N/A
—
5yr avg: 4.69
30Y Low0.2·High4.7
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CTKB Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Cytek Biosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $593M | $645M | $848M | $1.2B | $1.4B | $2.2B | — | — |
| Enterprise Value | $526M | $578M | $766M | $1.1B | $1.1B | $1.8B | — | — |
| P/E Ratio → | -8.87 | — | — | — | 548.92 | 494.55 | — | — |
| P/S Ratio | 2.94 | 3.20 | 4.23 | 6.39 | 8.62 | 17.06 | — | — |
| P/B Ratio | 1.72 | 1.89 | 2.14 | 3.14 | 3.32 | 5.38 | — | — |
| P/FCF | — | — | 38.79 | 2717.58 | — | 8205.99 | — | — |
| P/OCF | — | — | 33.40 | 233.63 | — | 471.45 | — | — |
P/E links to full P/E history page with 30-year chart
CTKB EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.87 | 3.82 | 5.60 | 6.93 | 14.21 | — | — |
| EV / EBITDA | — | — | — | — | 294.74 | 174.84 | — | — |
| EV / EBIT | — | — | — | — | 296.43 | 236.77 | — | — |
| EV / FCF | — | — | 35.05 | 2380.22 | — | 6835.25 | — | — |
CTKB Profitability
Margins and return-on-capital ratios measuring operating efficiency
Cytek Biosciences, Inc. earns an operating margin of -20.0%. Operating margins have compressed from -14.4% to -20.0% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -18.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.8% | 51.8% | 55.4% | 56.7% | 61.6% | 61.9% | 55.7% | 49.5% |
| Operating Margin | -20.0% | -20.0% | -10.2% | -14.4% | -1.1% | 7.2% | 14.7% | -29.8% |
| Net Profit Margin | -33.0% | -33.0% | -3.0% | -6.3% | 1.6% | 2.3% | 20.9% | -29.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -18.0% | -18.0% | -1.5% | -3.0% | 0.6% | 1.5% | — | — |
| ROA | -13.8% | -13.8% | -1.2% | -2.4% | 0.5% | 0.9% | 13.4% | -23.9% |
| ROIC | -10.3% | -10.3% | -5.6% | -10.8% | -1.4% | 16.8% | — | — |
| ROCE | -9.9% | -9.9% | -4.7% | -6.1% | -0.4% | 2.9% | 11.3% | -35.0% |
CTKB Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $91M exceeds total debt of $24M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.04 | 0.04 | 0.04 | — | — | — |
| Debt / EBITDA | — | — | — | — | 4.69 | — | 0.19 | — |
| Net Debt / Equity | — | -0.20 | -0.21 | -0.39 | -0.65 | -0.90 | — | — |
| Net Debt / EBITDA | — | — | — | — | -72.25 | -35.06 | -11.39 | — |
| Debt / FCF | — | — | -3.74 | -337.36 | — | -1370.74 | -11.94 | — |
| Interest Coverage | -61.96 | -61.96 | — | -6.59 | 1.49 | 4.41 | 44.33 | -16293.00 |
Net cash position: cash ($91M) exceeds total debt ($24M)
CTKB Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Cytek Biosciences, Inc.'s current ratio of 5.04x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 4.42x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 6.97x to 5.04x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.04 | 5.04 | 5.86 | 6.97 | 9.26 | 13.01 | 7.86 | 3.22 |
| Quick Ratio | 4.42 | 4.42 | 5.21 | 5.89 | 8.28 | 12.04 | 6.99 | 2.34 |
| Cash Ratio | 3.36 | 3.36 | 4.11 | 4.67 | 6.96 | 10.99 | 6.23 | 1.43 |
| Asset Turnover | — | 0.44 | 0.40 | 0.39 | 0.32 | 0.28 | 0.42 | 0.82 |
| Inventory Turnover | 2.00 | 2.00 | 2.04 | 1.37 | 1.31 | 1.52 | 1.79 | 1.58 |
| Days Sales Outstanding | — | 130.66 | 110.32 | 106.13 | 113.20 | 84.53 | 71.18 | 111.90 |
CTKB Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Cytek Biosciences, Inc. returns 2.5% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 0.2% | 0.2% | — | — |
| FCF Yield | — | — | 2.6% | 0.0% | — | 0.0% | — | — |
| Buyback Yield | 2.5% | 2.3% | 2.5% | 3.6% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 2.5% | 2.3% | 2.5% | 3.6% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $128M | $131M | $135M | $139M | $134M | $133M | $133M |
Peer Comparison
Compare CTKB with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CTKBYou | $593M | -8.9 | — | — | 51.8% | -20.0% | -18.0% | -10.3% | — |
 ILMN | $22B | 26.0 | 20.0 | 23.1 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 AZTA | $885M | -15.8 | 14.4 | 23.1 | 45.5% | -1.9% | -3.2% | -0.5% | 2.2 |
 NTRA | $28B | -127.8 | — | 252.3 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 BIO | $7B | 9.1 | 16.5 | 18.3 | 52.0% | 10.5% | 10.8% | 2.6% | 3.2 |
 BRKR | $7B | -294.4 | 18.6 | 155.2 | 45.9% | 6.9% | -0.4% | 4.4% | 4.5 |
 WAT | $23B | 33.0 | 21.8 | 42.9 | 57.8% | 28.2% | 29.3% | 20.3% | 1.3 |
 TMO | $173B | 26.2 | 18.7 | 27.5 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 A | $33B | 25.3 | 19.4 | 28.4 | 52.4% | 21.3% | 20.6% | 13.5% | 1.9 |
 MESO | $2B | -17.5 | — | — | 70.2% | -363.1% | -19.0% | -8.5% | — |
| Healthcare Median | — | 21.9 | 14.2 | 18.5 | 64.3% | -5.0% | -34.0% | -11.0% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See CTKB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CTKB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CTKB vs ILMN
Side-by-side business, growth, and profitability comparison vs Illumina, Inc..
Start ComparisonCTKB — Frequently Asked Questions
Quick answers to the most common questions about buying CTKB stock.
What is Cytek Biosciences, Inc.'s P/E ratio?
Cytek Biosciences, Inc.'s current P/E ratio is -8.9x. This places it at the 50th percentile of its historical range.
What is Cytek Biosciences, Inc.'s ROE?
Cytek Biosciences, Inc.'s return on equity (ROE) is -18.0%. The historical average is -4.1%.
Is CTKB stock overvalued?
Based on historical data, Cytek Biosciences, Inc. is trading at a P/E of -8.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Cytek Biosciences, Inc.'s profit margins?
Cytek Biosciences, Inc. has 51.8% gross margin and -20.0% operating margin.